TRDA Entrada Therapeutics, Inc. Insider Trading

Director Zeiher purchases 5.0K TRDA shares at $5.86; stock down -61.6% from 52-week high amid -87.9% revenue decline

Bernhardt G Zeiher, as a director, purchased 5,000 shares of Entrada Therapeutics at $5.86 on 2026-05-20, establishing an initial position in the company. The purchase comes as TRDA faces significant operational headwinds: quarterly revenue has collapsed to $875,000.00 against a net loss of $-39,717,000.00, with annual revenue declining -87.9% year-over-year. The stock has suffered steep declines, trading at $6.31 currently—down -61.6% from its 52-week high of $16.45 and -51.7% over the past 30 days. Zeiher's cross-ticker track record shows 1 prior buy with an average 90-day return of +37.8%, though this isolated prior transaction provides limited predictive value for performance at this specific ticker. The purchase reflects director participation in a distressed biotech name with severe revenue deterioration and consistent unprofitability.

10% Owner Baker Bros. Advisors buys 28,867 shares at $9.07 for $261.8K; fifth purchase in 10 days

Baker Bros. Advisors LP, a 10% owner of Entrada Therapeutics, executed 4 separate purchases totaling 28,867 shares for $261,846.12 on November 20, 2025, at $9.07 per share. This marks the fifth buy transaction from this insider in the past 10 days (following purchases on November 11-12), suggesting sustained accumulation. The stock has rebounded 44.8% over the prior 30 days and 76.3% over 90 days from depressed levels, trading 54.2% below its 52-week high of $21.59. Against this backdrop, the insider's recent pattern of consistent open-market purchases at the $9.07 level occurs after sharp recent gains, yet the company remains deeply unprofitable with $-44.1M in net income against $1.6M quarterly revenue. The significance is moderated by lack of measurable outcomes from the prior same-ticker trades (all within 9 days) and a cross-ticker track record showing negative average 30-day returns on prior buys.

Director PARMAR KUSH sold 200,000 shares of TRDA at $8.80 on 2025-11-14 for $1.76M, reducing stake by 6.3% to 2.96M shares.

PARMAR KUSH, a Director, executed a sale of 200,000 shares at $8.80 per share on 2025-11-14, reducing his holdings from 3.16M shares to 2.96M shares. The sale occurs at a price 59.2% below the 52-week high of $21.59, coinciding with a sharp 50.3% gain over the prior 30 days and 66.1% gain over 90 days. Entrada Therapeutics is a preclinical-stage company burning substantial cash (net income: $-44.1M in the latest quarter) against minimal revenue ($1.6M quarterly), which may constrain liquidity for many months ahead. The combination of recent price momentum recovery, a significant stake reduction by a director with access to material nonpublic information, and the company's unprofitable burn trajectory warrants investor scrutiny of whether the director's assessment of near-term prospects has shifted.

5AM Ventures V sold 200,000 shares (200.0K) of TRDA at $8.80, reducing stake to 2,963,066 shares; stock +50.3% in 30 days.

5AM Ventures V, a 10% owner, sold 200,000 shares (200.0K shares) at $8.80 on 2025-11-14, exiting 6.3% of its pre-transaction holdings of 3,163,066 shares (3.16M shares). The sale occurred after a sharp 30-day run of +50.3%, bringing the stock to $8.82 currently, yet still -59.2% from its 52-week high of $21.59. Entrada is an unprofitable clinical-stage company with net income of $-44,134,000.00 ($-44.1M) in the latest period, though annual revenue growth stands at +63.4%. This sale by a significant institutional holder during a rapid recovery phase, against a backdrop of net losses and substantial distance from year-high valuations, warrants investor attention to the sustainability of the recent momentum and the fund's confidence in the current trajectory.

Baker Bros. Advisors LP (10% owner) bought 178,044 shares for $1.4M at TRDA; holdings rise to 4.66M shares (+4.0%)

Baker Bros. Advisors LP executed 12 separate purchases totaling 178,044 shares for $1,352,586.66 across three trading days (Nov 10–12, 2025), raising its stake to 4,664,924 shares. The blended average price of $7.60 sits significantly below the current price of $8.01 and well below the 52-week high of $21.59, placing this acquisition in a depressed valuation window. However, this must be contextualized: the stock is down 62.9% from its 52-week high and has surged +37.9% over the past 30 days and +52.6% over 90 days, meaning the insider is buying into a recovery phase, not a trough. The company's fundamentals show acute distress (net loss of $44.1M against $1.6M quarterly revenue) offset partly by strong top-line growth of +63.4% year-over-year, suggesting a pre-revenue or heavy R&D stage biotech. Baker Bros.' cross-ticker track record shows 16 prior buys averaging +7.3% returns within 30 days, but 4 prior sells with an average 30-day return of +5094.6%, indicating past sell activity was poorly timed. The scale of this open-market purchase by a 10% owner—adding 4.0% to existing holdings—and the multi-day structured buying pattern warrant monitoring for any material non-public information, particularly given the company's size ($306.1M market cap) and negative profitability profile.